Hologic, Inc. (NASDAQ:HOLX) Given Average Rating of "Hold" by Analysts

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) has earned an average recommendation of "Hold" from the seventeen brokerages that are covering the company, MarketBeat reports. Ten investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $78.75.

Several research analysts have weighed in on the stock. Morgan Stanley lowered their price objective on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Stephens decreased their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Royal Bank Of Canada decreased their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Finally, Raymond James Financial restated an "outperform" rating and set a $71.00 price objective (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd.

Hologic Stock Up 1.5%

Hologic stock traded up $1.00 during mid-day trading on Thursday, reaching $66.85. The stock had a trading volume of 2,086,821 shares, compared to its average volume of 2,382,979. The firm has a market capitalization of $14.90 billion, a PE ratio of 28.21, a price-to-earnings-growth ratio of 2.38 and a beta of 0.55. Hologic has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The stock's 50-day simple moving average is $61.12 and its 200-day simple moving average is $63.63. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the business posted $1.03 EPS. Hologic's quarterly revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts forecast that Hologic will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, Director Martin D. Madaus acquired 5,445 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.88% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HOLX. Zions Bancorporation National Association UT bought a new position in shares of Hologic in the first quarter worth approximately $34,000. EverSource Wealth Advisors LLC increased its position in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Hologic in the first quarter worth approximately $42,000. Finally, Raiffeisen Bank International AG bought a new position in shares of Hologic in the fourth quarter worth approximately $49,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.